Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors

Published:2021-09-21 Issue:24 Volume:127 Page:4565-4573
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Foster Corey C.¹^ORCID,Couey Marcus A.²,Kochanny Sara E.³,Khattri Arun³,Acharya Rajesh K.³,Tan Yi‐Hung Carol³,Brisson Ryan J.⁴,Leidner Rom S.²,Seiwert Tanguy Y.⁵

Affiliation:

1. Department of Radiation Oncology Vanderbilt University Medical Center Nashville Tennessee

2. Robert W. Franz Cancer Center Providence Portland Medical Center Portland Oregon

3. Section of Hematology/Oncology Department of Medicine and Comprehensive Cancer Center University of Chicago Medicine Chicago Illinois

4. Department of Medicine Henry Ford Hospital Detroit Michigan

5. Departments of Oncology and Otolaryngology, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore Maryland

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33780

Reference34 articles.

1. Cancer statistics, 2020

2. Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025

3. Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers

5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibodies against endogenous retroviruses;Immunological Reviews;2024-08-17

2. Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study;Cancer Letters;2024-08

3. Unraveling the noncoding RNA landscape in glioblastoma: from pathogenesis to precision therapeutics;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-15

4. Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma;Cancer Medicine;2024-06

5. Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives;FUTURE ONCOL;2024